Evaluating Early FMT for Clostridioides difficile Infection

Clostridioides difficile infection (CDI) is a significant cause of healthcare-associated diarrhea in adults, with a troubling tendency to recur. Recurrence rates are reported to be between 15% and 25% after a first episode and can rise to as high as 65% after multiple recurrences. This recurrent nature of CDI leads to increased morbidity, reduced quality of life, and greater healthcare utilization.

Study Design and Objectives

A new study protocol, published in BMJ open, outlines a phase III clinical trial designed to evaluate the efficacy of early fecal microbiota transplantation (FMT) in treating CDI. The trial aims to determine whether the early introduction of oral FMT, following standard antibiotic therapy, can improve outcomes compared to standard therapy alone.

This multicenter, randomized, open-label trial will be conducted across eight clinical centers in Switzerland. It plans to enroll 100 adult patients who either have a first episode of CDI with risk factors for recurrence or have experienced a first recurrence. Participants will first receive the standard of care anti-CDI antibiotics—either vancomycin or fidaxomicin for 10 days—before being randomized into two groups: one receiving oral FMT and the other continuing with standard therapy alone.

Intervention and Expected Outcomes

The intervention group will receive FMT in the form of oral capsules within 12 hours to 4 days after completing antibiotic treatment. For non-severe cases, patients will take 15 to 20 capsules twice on two consecutive days. Those with severe CDI will receive an additional two-day course of FMT. The control group will not receive any additional treatment beyond the standard antibiotic regimen.

The primary endpoint of the study is the proportion of patients experiencing a CDI recurrence eight weeks after completing treatment. Secondary outcomes include early and late recurrence rates, sustained cure at six and twelve months, quality-adjusted life years, and recurrence-free and overall survival at twelve months. Exploratory analyses will also look at microbiota diversity, biomarker identification, and the assessment of immunologic and microbial predictors of recurrence.

Potential Impact and Limitations

Emerging evidence suggests that early FMT may improve sustained clinical cure rates and reduce recurrence of CDI, but its benefits when used after a first episode or first recurrence remain insufficiently studied. This trial could provide valuable insights into the timing and effectiveness of FMT as a treatment strategy for CDI.

However, the study does have limitations. With a relatively small sample size of 100 participants, the findings may not be generalizable to all populations. Additionally, as an open-label trial, there is a potential for bias in reporting outcomes. The study's results will need to be interpreted in the context of these limitations.

For more on how antibiotics affect the gut microbiome, see our post on antibiotics and gut microbiome recovery.